Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Previous studies have demonstrated efficacy and safety of oral alitretinoin in hand eczema (HE) whereas in palmoplantar pustulosis (PPP), which can be difficult to distinguish from HE, efficacy of alitretinoin is still controversial. Objective: This study aimed to investigate the efficacy and safety of oral alitretinoin in HE and PPP and factors that affect the response of these disorders to alitretinoin. Methods: We retrospectively analyzed Korean adult patients with moderate-to-severe HE and PPP treated with oral alitretinoin, 46 patients for efficacy assessment and 55 patients for safety assessment. Results: Among 46 patients who were treated with alitretinoin for at least 1 month, 29 patients (61.1% in HE and 40.0% in PPP) showed response to alitretinoin in the median 14 weeks after treatment. Hyperkeratotic HE showed higher response rate than either vesicular HE or PPP (p=0.026 and p=0.026, respectively). However, PPP with hyperkeratotic features showed as much response as hyperkeratotic HE (p=0.554). When responders and non-responders in total patients were compared, morphology, not diagnosis or initial severity, was the only significantly different factor between the two groups. After alitretinoin discontinuation in responders, relapse rate was 63.6% (7/11) and median time to relapse was 150 days (range, 76∼730 days). Adverse events occurred in 47.3% (26/55); however, there were no serious adverse events. Conclusion: In HE or PPP, lesions with hyperkeratotic morphology can be predicted to respond well to alitretinoin regardless of diagnosis.
Abstract
Background: Previous studies have demonstrated efficacy and safety of oral alitretinoin in hand eczema (HE) whereas in palmoplantar pustulosis (PPP), which can be difficult to distinguish from HE, efficacy of alitretinoin is still controversial. Objective: This study aimed to investigate the efficacy and safety of oral alitretinoin in HE and PPP and factors that affect the response of these disorders to alitretinoin. Methods: We retrospectively analyzed Korean adult patients with moderate-to-severe HE and PPP treated with oral alitretinoin, 46 patients for efficacy assessment and 55 patients for safety assessment. Results: Among 46 patients who were treated with alitretinoin for at least 1 month, 29 patients (61.1% in HE and 40.0% in PPP) showed response to alitretinoin in the median 14 weeks after treatment. Hyperkeratotic HE showed higher response rate than either vesicular HE or PPP (p=0.026 and p=0.026, respectively). However, PPP with hyperkeratotic features showed as much response as hyperkeratotic HE (p=0.554). When responders and non-responders in total patients were compared, morphology, not diagnosis or initial severity, was the only significantly different factor between the two groups. After alitretinoin discontinuation in responders, relapse rate was 63.6% (7/11) and median time to relapse was 150 days (range, 76∼730 days). Adverse events occurred in 47.3% (26/55); however, there were no serious adverse events. Conclusion: In HE or PPP, lesions with hyperkeratotic morphology can be predicted to respond well to alitretinoin regardless of diagnosis.
참고문헌 (22)
- Fowler JF, "A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization", Cutis, 77, pp.385~392 (2006)
- Meding B, "Hand eczema in Swedish adults-changes in prevalence between 1983 and 1996", J Invest Dermatol, 118, pp.719~723 (2002)
- Diepgen TL, "Hand eczema classification : a cross-sectional, multicentre study of the aetiology and morphology of hand eczema", Br J Dermatol, 160, pp.353~358 (2009)
- Agner T, "Hand eczema severity and quality of life : a cross-sectional, multicentre study of hand eczema patients", Contact Dermatitis, 59, pp.43~47 (2008)
- Misiak-Galazka M, "What do we know about palmoplantar pustulosis", J Eur Acad Dermatol Venereol, 31, pp.38~44 (2017)
- Yoon SY, "Histological differentiation between palmoplantar pustulosis and pompholyx", J Eur Acad Dermatol Venereol, 27, pp.889~893 (2013)
- Mrowietz U, "Management of palmoplantar pustulosis : do we need to change", Br J Dermatol, 164, pp.942~946 (2011)
- Diepgen TL, "Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions : results of the TOCCATA open study comprising 680 patients", Acta Derm Venereol, 92, pp.251~255 (2012)
- Ruzicka T, "Efficacy and safety of oral alitretinoin(9-cis retinoic acid)in patients with severe chronic hand eczema refractory to topical corticosteroids : results of a randomized, double-blind, placebo-controlled, multicentre trial", Br J Dermatol, 158, pp.808~817 (2008)
- Dirschka T, "An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids", Clin Exp Dermatol, 36, pp.149~154 (2011)
- 권형일, "Efficacy and Safety of Alitretinoin for Chronic Hand Eczema in Korean Patients", Annals of Dermatology, 28(3), pp.364~370 (2016), 대한피부과학회
- Reich K, "Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment : a randomized phase II study", Br J Dermatol, 174, pp.1277~1281 (2016)
- Irla N, "Alitretinoin abrogates innate inflammation in palmoplantar pustular psoriasis", Br J Dermatol, 167, pp.1170~1174 (2012)
- 장시혁, "Helpful Clinical Features for Differential Diagnosis of Palmoplantar Pustulosis and Pompholyx", 대한피부과학회지, 55(1), pp.36~44 (2017), 대한피부과학회
- Park JY, "The histopathological differentiation between palmar psoriasis and hand eczema : a retrospective review of 96 cases", J Am Acad Dermatol, 77, pp.130~135 (2017)
- Aydin O, "Non-pustular palmoplantar psoriasis : is histologic differentiation from eczematous dermatitis possible", J Cutan Pathol, 35, pp.169~173 (2008)
- Agner T, "Classification of hand eczema", J Eur Acad Dermatol Venereol, 29, pp.2417~2422 (2015)
- Germain P, "International Union of Pharmacology. LXIII. Retinoid X receptors", Pharmacol Rev, 58, pp.760~772 (2006)
- Germain P, "International Union of Pharmacology. LX. Retinoic acid receptors", Pharmacol Rev, 58, pp.712~725 (2006)
- Hanifin JM, "Novel treatment of chronic severe hand dermatitis with bexarotene gel", Br J Dermatol, 150, pp.545~553 (2004)
- Thestrup-Pedersen K, "Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebocontrolled study", Acta Derm Venereol, 81, pp.353~355 (2001)
- Shi VY, "Alitretinoin for the treatment of chronic hand eczema: clinical rationale", Clin Invest(Lond), 4, pp.763~773 (2014)